MTOR and pulmonary arterial hypertension: The mTOR pathway is a major research focus for a variety of diseases including an ongoing clinical trial with the mTOR inhibitor, rapamycin in PAH (Houssaini et al., 2013; Arriola Apelo and Lamming, 2016).